# US 8,278,314 B2 · Quinazoline analogs as receptor tyrosine kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,314 B2
- Document ID: US8278314B2
- Status: Granted
- Kind: B2
- Application number: 12/249,421
- Filed: 2008-10-10
- Published: 2009-02-19
- Granted: 2012-10-02
- Earliest claimed: 2003-08-14
- Assignees: Array BioPharma Inc.
- Inventors: Eli Wallace; George Topalov; Joseph Lyssikatos; Alexandre Buckmelter; Qian Zhao
- Web page: https://patentgrep.com/patent/US8278314B2

## CPC

- C07D 239/94: Nitrogen atoms
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C04B 35/632: Organic additives
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE

## Abstract

This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

## Claims

### Claim 1

A compound comprising Formula I:
or resolved enantiomers, diastereomers and pharmaceutically acceptable salts thereof,
wherein A is bonded to at least one of the carbons at positions 5, 6, 7 or 8 of the bicyclic ring and wherein the bicyclic ring is substituted by zero, one or two independent R3 groups;
X is N;
A is Q;
Q is
R1 is a substituted or unsubstituted, monocyclic or bicyclic, aryl or heteroaryl moiety;
R2 is H or a substituted or unsubstituted C1-8 alkyl, allyl, substituted benzyl;
R3 is hydrogen, halogen, cyano, nitro, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl, heterocyclylalkyl, —NR4SO2R5—SO2NR6R4, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR4C(O)OR5, —NR4C(O)R6, —C(O)NR4R6, —NR4R6, —NR4C(O)NR4R6, —OR6, —S(O)R5, —SO2R5, or SR6, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl, and heterocyclylalkyl is optionally substituted with one to five groups independently selected from the group consisting of oxo, halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR4SO2R5, —SO2NR6R4, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR4C(O)OR5, —NR4C(O)CR6, —C(O)NR4R6, —NR4R6, NR4C(O)NR4R6, —NR4C(NCN)NR4R6, —OR6, —S(O)R5, —SO2R5, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R10 is hydrogen, halogen, cyano, nitro, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, partially unsaturated heterocyclyl —NR4SO2R5—SO2NR6R4, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR4C(O)OR5, —NR4C(O)R6, —C(O)NR4R6, —NR4R6, —NR4C(O)NR4R6, —OR6, —S(O)R5, —SO2R5, or SR6, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or partially unsaturated heterocyclyl is optionally substituted with one to five groups independently selected from the group consisting of oxo, halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR4SO2R5, —SO2NR6R4, —C(O)R6, —C(O)OR6, —OC(O)R6, —NR4C(O)OR5, —NR4C(O)CR6, —C(O)NR4R6, —NR4R6, NR4C(O)NR4R6, —NR4C(NCN)NR4R6, —OR6, —S(O)R5, —SO2R5, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, wherein g is 1 to 3 and each R10 can be the same or different,
or one or more of said R10 groups are independently joined together with the atoms to which they are attached to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO2 and NR6, where each ring carbon is optionally substituted with one to three groups independently selected from the group consisting of halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR8, NR6R8, SR6, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms;
R4 is H or C1-6 alkyl;
R5 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, or partially unsaturated heterocycle, wherein said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl, and heterocyclylalkyl is optionally substituted with one to five groups independently selected from the group consisting of oxo, halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, OR6, NR4R6, SR6, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 and R8 are independently selected from the group consisting of hydrogen, trifluoromethyl, C1-C10 alkyl, (CH2)0-4C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, wherein said alkyl, cycloalkyl, aryl, aryl alkyl, hetero aryl, heterocyclyl, partially unsaturated heterocyclyl, and heterocyclylalkyl is optionally substituted with one to five groups independently selected from the group consisting of oxo, halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl;
or R4 and R6 together with the atoms to which they are attached may be independently joined to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO2 and NR6, wherein each ring carbon is optionally substituted with one to three groups independently selected from the group consisting of halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR8, NR6R8, SR6, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms;
or R6 and R8 together with the atoms to which they are attached may be independently joined to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO2 and NR6, wherein each ring carbon is optionally substituted with one to three groups independently selected from the group consisting of halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR8, NR6R8, SR6, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms;
or R6 and R10 together with the atoms to which they are attached may be independently joined to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO2 and NR6, wherein each ring carbon may be optionally substituted with one to three groups independently selected from the group consisting of halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR8, NR6R8, SR6, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms;
or R8 and R10 together with the atoms to which they are attached may be independently joined to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO2 and NR6, wherein each ring carbon may be optionally substituted with one to three groups independently selected from halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR8, NR6R8, SR6, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is bonded to at least one of the carbons at the 6 or 7 position of the bicyclic ring.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R2 is hydrogen, and R3 is hydrogen or OR6.

### Claim 4 (depends on 2)

The compound of claim 2, wherein R2 is hydrogen.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R1 is selected from the structures:

### Claim 6 (depends on 3)

The compound of claim 3, wherein Q is selected from the structures:

### Claim 7 (depends on 1)

The compound of claim 1, wherein Formula I is selected from the structures:
or pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 7)

The compound of claim 7 having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 7)

The compound of claim 7 having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 7)

The compound of claim 7 having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 7)

The compound of claim 7 having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 7)

The compound of claim 7 having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 14 (depends on 7)

A pharmaceutical composition comprising a compound as defined in claim 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
